Overview

The Effect Of Aspirin On Survival in Lung Cancer

Status:
Withdrawn

Trial end date:
2020-08-01

Target enrollment:
0

Participant gender:
All

Summary

Lung cancer is the most common cancer in the western world. Only 10 to 15 % of patients diagnosed with lung cancer are suitable for potentially curative surgical treatment. Despite surgery, recurrence of lung cancer still occurs. Aspirin potentially may help increase survival by altering the biochemistry of any potential remaining lung cancer cells. Most lung cancer occurs in smokers. Smokers are at increased risk of heart attacks and strokes. Aspirin has beneficial effects on the heart and brain, potentially reducing the incidence of heart attacks and strokes.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Liverpool Heart and Chest Hospital NHS Foundation Trust

Treatments:

Aspirin

Criteria

Inclusion Criteria:

- All patients aged 18 to 85, undergoing potentially curative resection of non small
cell carcinoma of the lung, who have none of the following exclusion criteria.

Exclusion Criteria:

- Already on aspirin Small cell carcinoma N2 disease Confirmed metastatic disease
Incomplete resections Previous cancer in last 3 years History of gastric or duodenal
ulcers Known allergy to aspirin or other NSAIDs.